Clinical Trial Update: Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers. [Phase 2]

View source ↗

Summary

Phase 2 trial assessing immunogenicity, safety and tolerability of a bivalent recombinant lipoprotein vaccine (rLP2086) for meningococcal B disease in healthy t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease Meningococcal Disease

Drugs mentioned

• Bivalent rLP2086 (rLP2086 (N. meningitidis outer membrane protein complex))

Snippet

Sponsor: Pfizer | Conditions: Meningococcal B Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-04-17